Can a Triple-Drug cocktail outsmart Treatment-Resistant colorectal cancer?
NCT ID NCT05167409
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding an experimental drug called evorpacept to two existing cancer drugs (cetuximab and pembrolizumab) can shrink tumors in people with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study enrolls adults with microsatellite stable metastatic colorectal cancer, a form that typically does not respond well to immunotherapy. The goal is to see if the combination can trigger tumor shrinkage and control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of three drugs: evorpacept, cetuximab, and pembrolizumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with a hard-to-treat form of colorectal cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits and risks are not yet well understood. The drug combination may cause significant side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSATELLITE STABLE METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Rutgers Cancer insititute
New Brunswick, New Jersey, 08903, United States
-
University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.